pandemic influenza vaccine (H1N1) (split virion, inactivated, adjuvanted)

Pandemrix is an inactivated, split-virion influenza vaccine developed by GSK specifically for the 2009 H1N1 influenza pandemic. It contains the A/California/7/2009 (H1N1)v-like strain. A key feature of Pandemrix is the use of the AS03 adjuvant system, an oil-in-water emulsion containing squalene, DL-alpha-tocopherol, and polysorbate 80, which was designed to enhance the immune response and allow for dose-sparing. The vaccine was authorized by the European Medicines Agency (EMA) in September 2009. However, post-marketing surveillance revealed an increased risk of narcolepsy, particularly in children and adolescents in several European countries, leading to restricted use and eventual discontinuation of the product.

Brand names

Pandemrix

Other names

H1N1 pandemic vaccineH-1N1 pandemic vaccineH 1N1 pandemic vaccineA/H1N1v vaccine